Ignite Creation Date:
2024-05-06 @ 8:48 AM
Last Modification Date:
2024-10-26 @ 12:05 PM
Study NCT ID:
NCT02827344
Status:
COMPLETED
Last Update Posted:
2023-08-29
First Post:
2016-07-06
Brief Title:
PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer
Sponsor:
University Hospital Toulouse
Organization:
University Hospital Toulouse
Study Overview
Official Title:
Feasibility Study of PD-L1 Expression Analysis on Circulating Tumor Cells by Immunocytochemistry and MDSCs Level Evolution Analysis in Non-small Cell Lung Cancer Treated With PD-L1 or PD1 Inhibitor
Status:
COMPLETED
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IMMUNO-PREDICT
Brief Summary:
Immunotherapy is probably since the development of therapies targeting EGFR mutations or ALK rearrangement the most attractive therapeutic perspective in the management of metastatic lung cancer Among the compounds tested the inhibitors of the immune checkpoint PROGRAMME DEATH 1 PROGRAMME DEATH LIGAND 1 PD-1PD-L1 have been tested in numerous clinical trials with recently published positive results leading to the approval of one drug in the USA and an expanded access program for two drugs in France PROGRAMME DEATH LIGAND 1 PD-L1 expression by tumor cells is strongly associated with the response to such molecules so that the participation in various clinical trials is currently reserved for patients expressing this biomarker and therefore justifies a new invasive biopsy bronchoscopic or CT-guided representing a considerable drag on the access to these treatments Circulating tumor cells CTCs isolated by Isolation by Size of Tumor Cells ISET offer a direct and non-invasive access to the tumor It has already been demonstrated that molecular characterization EGFR ALK on these blood samples is possible We propose to demonstrate the feasibility of the analysis PDL-1 expression in these cells by immunocytochemistry
Myeloid-Derived Suppressor Cells MDSCs are immature myeloid cells that inhibit T cell functions and thus promote tumor growth These cells frequently express PD-L1 We propose to test whether MDSCs level and its evolution during treatment with PD1 inhibitor is correlated to the response to these drugs
The main objective of this study is to demonstrate the feasibility of the analysis of PD-L1 expression on CTC
Myeloid-Derived Suppressor Cells MDSCs are immature myeloid cells that inhibit T cell functions and thus promote tumor growth These cells frequently express PD-L1 We propose to test whether MDSCs level and its evolution during treatment with PD1 inhibitor is correlated to the response to these drugs
The main objective of this study is to demonstrate the feasibility of the analysis of PD-L1 expression on CTC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None